Vistagen Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Vistagen Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Fasedienol Nasal Spray in Social Anxiety Disorder (Phase 3).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| AV-101 | Neuropathic Pain | n/a | Phase 1 | Public pipeline row |
| Fasedienol Nasal Spray | Social Anxiety Disorder | n/a | Phase 3 | Public pipeline row |
| AV-101 720 mg | Healthy | n/a | Phase 1 | Phase 2 | Public pipeline row |
| PH94B | Social Anxiety Disorder | n/a | Phase 3 | Public pipeline row |
| PH94B Nasal Spray | Social Anxiety Disorder | n/a | Phase 3 | Public pipeline row |
No public catalyst rows matched this view yet.
Estimated cash runway: Unknown.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT01483846 | Phase 1 | COMPLETED | 50 | 2012-09 |
| NCT03583554 | Phase 1 | Phase 2 | COMPLETED | 18 | 2019-10-19 |
| NCT04754802 | Phase 3 | COMPLETED | 224 | 2022-06-22 |
| NCT05011396 | Phase 3 | TERMINATED | 228 | 2022-08-16 |
| NCT05280054 | Phase 1 | UNKNOWN | 24 | 2022-09-01 |
| NCT05030350 | Phase 3 | TERMINATED | 481 | 2022-09-23 |
| NCT04147949 | Phase 2 | UNKNOWN | 20 | 2023-12 |
| NCT06358651 | Phase 3 | ACTIVE_NOT_RECRUITING | 238 | 2025-10-31 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.